 |
Prospector
Profile
c05
|
| |
| Poniard Pharmaceuticals, Inc. |
NAICS |
325400 |
| 7000 Shoreline Court Suite 270
South San Francisco, CA 94080 |
Description |
|
| (650) 853-3774 |
Employees |
|
| http://www.poniard.com/ |
Revenue |
|
$ 0.00 |
| |
Income |
|
$ 48.56 |
| |
Assets |
|
$ 84.23 |
| |
Liability |
|
$ 36.59 |
| |
(for the year ended - 12-31-2008) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Poniard Pharmaceuticals, Inc., reported a net loss of $9.9 million for the quarter ended Sept. 30, 2009, compared with a net loss of $12.2 million for the quarter ended Sept. 30, 2008.The Company reported a net loss of $32.5 million for the nine months ended Sept. 30, 2009, compared with a net loss of $34.6 million for the same period in 2008. As of Sept. 30, 2009, the Company's consolidated balance sheets showed total assets of $49.6 million, total liabilities of $29.4 million, and total shareholders' equity of $20.2 million.
The Company has historically experienced recurring operating losses and negative cash flows from operations. As of Sept. 30, 2009, the Company had working capital of $23.7 million, an accumulated deficit of $394.9 million and total shareholders' equity of $20.2 million. The Company believes that these factors, among others, raise substantial doubt about its ability to continue as a going concern.
|
| |
|
Intellectual Property:
Poniard Pharmaceuticals, Inc., has filed applications for United States and foreign patents on many aspects of its technologies. The Company holds an exclusive worldwide license granted from Genzyme Corporation for the development and commercial sale of picoplatin. [SEC Filing 10-K 03-16-09]
|
| |
|
Description:
Poniard Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of cancer therapy products. Its lead product candidate is picoplatin, a platinum-based cancer therapy. NeoRx Manufacturing Group, Inc. is a wholly owned subsidiary of the Company.
|
| |
|
Officers:
Gerald McMahon (Chair. & CEO); Ronald A. Martell (Pres. & COO); Gregory L. Weaver (SVP & CFO); Robert L. De Jager (CMO)
|
| |
|
Auditor:
KPMG LLP
|
| |
|
Securities:
Common Stock Symbol PARD;Nasdaq; 34,961,497 shares of common stock outstanding as of Oct. 30, 2009.
$27.6 million senior secured term loan facility.
|
| |
| |
| |
| return to main page |
|
|
